|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 1/19/23 Accustem Sciences Inc. S-1/A 57:7M M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size
1: S-1/A Pre-Effective Amendment to Registration Statement HTML 2.19M
(General Form)
2: EX-5.1 Opinion of Counsel re: Legality HTML 29K
3: EX-23.1 Consent of Expert or Counsel HTML 16K
4: EX-FILING FEES Filing Fees HTML 24K
10: R1 Cover HTML 57K
11: R2 Consolidated Balance Sheets HTML 105K
12: R3 Consolidated Balance Sheets (Parenthetical) HTML 35K
13: R4 Consolidated Statements of Operations and HTML 66K
Comprehensive Income (Loss)
14: R5 Consolidated Statements of Shareholders' Equity HTML 80K
15: R6 Consolidated Statements of Cash Flows HTML 95K
16: R7 Nature of Business HTML 50K
17: R8 Summary of Significant Accounting Policies HTML 75K
18: R9 Acquisition of Stemprinter Sciences Limited and HTML 33K
Equity Raise
19: R10 Note Payable HTML 25K
20: R11 Equipment HTML 26K
21: R12 License HTML 38K
22: R13 Loss Per Share HTML 67K
23: R14 Share-Based Compensation HTML 187K
24: R15 Related Party Transactions HTML 32K
25: R16 Income Taxes HTML 102K
26: R17 Commitments and Contingencies HTML 23K
27: R18 Subsequent Events HTML 26K
28: R19 Summary of Significant Accounting Policies HTML 117K
(Policies)
29: R20 Equipment (Tables) HTML 23K
30: R21 Loss Per Share (Tables) HTML 64K
31: R22 Share-Based Compensation (Tables) HTML 161K
32: R23 Income Taxes (Tables) HTML 90K
33: R24 Nature of Business (Details Narrative) HTML 69K
34: R25 Summary of Significant Accounting Policies HTML 23K
(Details Narrative)
35: R26 Acquisition of Stemprinter Sciences Limited and HTML 37K
Equity Raise (Details Narrative)
36: R27 Note Payable (Details Narrative) HTML 32K
37: R28 Schedule of Property and Equipment (Details) HTML 25K
38: R29 Equipment (Details Narrative) HTML 19K
39: R30 License (Details Narrative) HTML 25K
40: R31 Schedule of Loss Per Share (Details) HTML 44K
41: R32 Schedule of Computation of Diluted Net Loss Per HTML 23K
Share (Details)
42: R33 Schedule of Stock Option Activity (Details) HTML 73K
43: R34 Schedule of Stock Based Compensation Expenses HTML 24K
(Details)
44: R35 Schedule of Stock Valuation Assumptions (Details) HTML 42K
45: R36 Schedule of Warrants Outstanding (Details) HTML 51K
46: R37 Share-Based Compensation (Details Narrative) HTML 80K
47: R38 Related Party Transactions (Details Narrative) HTML 47K
48: R39 Schedule of Domestic and Foreign Components of HTML 28K
Loss Before Income Taxes (Details)
49: R40 Schedule of Reconciliation Provision for Income HTML 30K
Taxes (Details)
50: R41 Schedule of Deferred Income Tax Assets (Details) HTML 25K
51: R42 Income Taxes (Details Narrative) HTML 27K
52: R43 Subsequent Events (Details Narrative) HTML 40K
55: XML IDEA XML File -- Filing Summary XML 99K
53: XML XBRL Instance -- forms-1a_htm XML 1.34M
54: EXCEL IDEA Workbook of Financial Reports XLSX 104K
6: EX-101.CAL Inline XBRL Taxonomy Extension Calculation XML 108K
Linkbase Document -- acut-20220930_cal
7: EX-101.DEF Inline XBRL Taxonomy Extension Definition Linkbase XML 404K
Document -- acut-20220930_def
8: EX-101.LAB Inline XBRL Taxonomy Extension Label Linkbase XML 718K
Document -- acut-20220930_lab
9: EX-101.PRE Inline XBRL Taxonomy Extension Presentation XML 561K
Linkbase Document -- acut-20220930_pre
5: EX-101.SCH Inline XBRL Taxonomy Extension Schema Document -- XSD 89K
acut-20220930
56: JSON XBRL Instance as JSON Data -- MetaLinks 295± 442K
57: ZIP XBRL Zipped Folder -- 0001493152-23-001932-xbrl Zip 644K
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We hereby consent to the use in this Amendment No. 1 to the Registration Statement on Form S-1 of our report dated April 15, 2022, related to the consolidated financial statements of Accustem Sciences, Inc. as of December 31, 2021 and 2020 and for the year ended December 31, 2021 and the period from June 5, 2020 (date of inception) to December 31, 2020, which appears in this Registration Statement of Accustem Sciences, Inc. and Subsidiary. The report for Accustem Sciences, Inc. and Subsidiary includes an explanatory paragraph about the existence of substantial doubt about its ability to continue as a going concern. We also consent to the reference to our Firm under the caption “Experts” in such Registration Statement.
/s/ Mazars USA LLP
New York, New York
C:
| This ‘S-1/A’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 1/19/23 | |||
| 4/15/22 | ||||
| 12/31/21 | 10-K, NT 10-K | |||
| 12/31/20 | ||||
| 6/5/20 | ||||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/17/22 Accustem Sciences Inc. S-1 66:33M M2 Compliance LLC/FA 9/14/22 Accustem Sciences Inc. DEF 14A 9/14/22 1:354K M2 Compliance LLC/FA 12/03/21 Accustem Sciences Inc. 8-K:1,2,3,512/01/21 7:813K M2 Compliance LLC/FA 3/12/21 Accustem Sciences Inc. 20FR12G 8:2.2M Donnelley … Solutions/FA |